Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy - Case Report.
Thyrotoxicosis
congestive heart failure
heart rate
ivabradine
sinus tachycardia
thyrotoxic cardiomyopathy
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
05
2022
revised:
30
08
2022
accepted:
17
10
2022
medline:
22
5
2023
pubmed:
16
12
2022
entrez:
15
12
2022
Statut:
ppublish
Résumé
Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents. However, when thyrotoxicosis is not controlled, heart rate may be difficult to control even with maximal doses of propranolol. This presentation alerts physicians to the possibility of using ivabradine, a selective inhibitor of the sinoatrial pacemaker, for the control of heart rate. We present a 37-year-old woman with thyrotoxicosis and congestive heart failure whose heart rate was not controlled with a maximal dose of beta blockers during a thyroid storm. The addition of ivabradine, a selective inhibitor of the sinoatrial pacemaker, controlled her heart rate within 48 hours. Ivabradine should be considered in patients with thyrotoxicosis, including those with heart failure, in whom beta blockers are insufficient to control heart rate.
Sections du résumé
BACKGROUND
BACKGROUND
Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents. However, when thyrotoxicosis is not controlled, heart rate may be difficult to control even with maximal doses of propranolol. This presentation alerts physicians to the possibility of using ivabradine, a selective inhibitor of the sinoatrial pacemaker, for the control of heart rate.
CASE PRESENTATION
METHODS
We present a 37-year-old woman with thyrotoxicosis and congestive heart failure whose heart rate was not controlled with a maximal dose of beta blockers during a thyroid storm. The addition of ivabradine, a selective inhibitor of the sinoatrial pacemaker, controlled her heart rate within 48 hours.
CONCLUSION
CONCLUSIONS
Ivabradine should be considered in patients with thyrotoxicosis, including those with heart failure, in whom beta blockers are insufficient to control heart rate.
Identifiants
pubmed: 36518043
pii: EMIDDT-EPUB-128260
doi: 10.2174/1871530323666221214141205
doi:
Substances chimiques
Ivabradine
3H48L0LPZQ
Adrenergic beta-Antagonists
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-995Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.